Jalon Therapeutics manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology.
Lead candidate JRT39 was selected based on optimized sequence, superior preclinical efficacy and preliminary stability & PK profiles.
Discovery-stage candidates display differentiated modes of action (MoAs) supporting multiple therapeutic applications.